The linear progression through generations of BTK inhibitors may be a flawed strategy, as indefinite kinase blocking is unsustainable. The future likely lies in BTK degraders, a new drug class that eliminates the target protein entirely, offering a novel approach to overcoming resistance instead of just inhibiting the protein.

While second-generation BTK inhibitors are clinically similar, the next major advance in combination therapy may come from the BCL2 inhibitor component. The newer agent sonrotoclax is potentially more potent and selective than venetoclax, which could lead to superior efficacy and tolerability in future regimens.

BTK degraders work despite most kinase inhibitor resistance mutations. However, resistance to degraders themselves alters the BTK binding pocket so significantly that subsequent targeting with any BTK kinase inhibitor is unlikely to be effective, positioning them as a potential end-of-line therapy.

When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.

Despite advancements from first-generation (ibrutinib) to second-generation (acalabrutinib) BTK inhibitors, a consistent pattern emerges: the rate of complete responses plateaus around 36% over time. This suggests a potential biological limit for this class of drugs when used as monotherapy in CLL.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

The UK FLAIR trial demonstrated for the first time that a time-limited regimen (ibrutinib-venetoclax), guided by MRD to a median duration of 27 months, achieved superior progression-free and overall survival compared to continuous ibrutinib therapy in frontline CLL.

While the continuous BTK inhibitor zanubrutinib showed longer progression-free survival, this efficacy came with a significant safety trade-off. It led to a 47% rate of serious adverse events compared to 24% for the fixed-duration acalabrutinib-venetoclax combination in the indirect analysis.

The CLL17 study reveals that continuous ibrutinib, fixed-duration venetoclax/obinutuzumab, and fixed-duration venetoclax/ibrutinib all yield identical progression-free survival rates at three years. This finding empowers clinicians to choose a strategy based on patient preference (continuous vs. fixed-duration) without compromising near-term efficacy.